Angiotensin inhibition stimulates PPARγ and the release of visfatin

European Journal of Clinical Investigation

Volumn 38, Issue 11, 2008, Pages 820-826

  Storka, A ^a   Vojtassakova, E ^a   Mueller, M ^b   Kapiotis, S ^a   Haider, D G ^a   Jungbauer, A ^b   Wolzt, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin receptor antagonist; Peroxisome proliferator activated receptor gamma; Visfatin

Indexed keywords

GROWTH FACTOR RECEPTOR; LISINOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; ROSIGLITAZONE; TELMISARTAN; VALSARTAN; VISFATIN;

ADIPOCYTE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WESTERN BLOTTING;

ADIPOCYTES; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOTTING, WESTERN; ENDOTHELIAL CELLS; HUMANS; INTRA-ABDOMINAL FAT; LISINOPRIL; MUSCLE, SKELETAL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PPAR GAMMA; RECEPTOR, IGF TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIAZOLIDINEDIONES; UMBILICAL VEINS; VALINE;

EID: 54349083077     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02025.x     Document Type: Article

References (38)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 : 645 50.
2. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000 26 : 76 80.
3. Barroso I, Luan J, Middelberg RP, Harding AH, Franks PW, Jakes RW et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. Plos Biol 2003 1 : E20.
4. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004 64 : 2537 65.
5. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 109 : 2054 7.
6. Scheen AJ, Paquot N. PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases. Rev Med Liege 2005 60 : 89 95.
7. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004 27 : 1015.
8. Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens 1995 9 (Suppl. 5 S45 50.
9. Moan A, Risanger T, Eide I, Kjeldsen SE. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994 3 : 185 8.
10. Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualdiero P, Varricchio G et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997 11 : 307 12.
11. Higashiura K, Ura N, Miyazaki Y, Shimamoto K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999 13 (Suppl. 1 S71 4.
12. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 1998 46 : 467 71.
13. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998 32 : 616 20.
14. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C et al. Liver-Specific PPAR{alpha}-Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan. Diabetes 2008 : Epub ahead.
15. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007 7 : 140 5.
16. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG et al. Effect of PPAR-alpha and - gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005 336 : 747 53.
17. Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G et al. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab 2006 291 : E885 90.
18. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973 52 : 2745 56.
19. Jungbauer A GK. The logistic dose-response function: a robust fitting function for transition phenomena in life sciences. J Clin Ligand Assay 2001 24 : 270 4.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976 72 : 248 54.
21. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997 52 : 115 20.
22. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000 28 : 149 67.
23. Neubeck M, Fliser D, Pritsch M, Weisser K, Fliser M, Nussberger J et al. Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment. Eur J Clin Pharmacol 1994 46 : 537 43.
24. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003 17 : 662 76.
25. Wang M, Tafuri S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 2003 89 : 38 47.
26. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 2005 19 : 453 61.
27. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999 31 : 2049 61.
28. Ren J, Duan J, Hintz KK, Ren BH. High glucose induces cardiac insulin-like growth factor I resistance in ventricular myocytes: role of Akt and ERK activation. Cardiovasc Res 2003 57 : 738 48.
29. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE et al. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 2002 110 : 1011 9.
30. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 2001 15 : 1926 34.
31. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H et al. Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia 2004 47 : 871 7.
32. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005 307 : 426 30.
33. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005 54 : 2911 6.
34. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V, Gogg S, Jansson P-A, Laakso M et al. Visfatin is an adipokine, but it is not regulated by Thiazolidinediones. J Clin Endocrinol Metab 2006 91 : 1181 4.
35. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006 91 : 1578 81.
36. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M et al. Serum concentration of visfatin in obese women. Metabolism 2007 56 : 1131 4.
37. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007 92 : 4783 91.
38. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006 49 : 1909 14.